کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2125705 1547272 2007 9 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
پیش نمایش صفحه اول مقاله
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
چکیده انگلیسی

Targeting of epidermal growth factor receptor (EGFR) and HER2 is a proven anti-cancer strategy. However, heterodimerisation, compensatory ‘crosstalk’ and redundancy exist in the ErbB network, and there is therefore a sound scientific rationale for dual inhibition of EGFR and HER2. Trials of approved agents in combination, for example trastuzumab and cetuximab, are underway. There is also a new generation of small molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mABs) that target two or more ErbB receptors. Lapatinib, a TKI of EGFR and HER2, has shown clinical benefit in trastuzumab refractory breast cancer and is poised for FDA approval. Other agents include BIBW-2992 and HKI-272, irreversible TKIs of EGFR and HER2, and pertuzumab, a heterodimerisation inhibitor of EGFR and HER2.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Cancer - Volume 43, Issue 3, February 2007, Pages 481–489
نویسندگان
, , , ,